KR102410090B1 - 항-ｃｔｌａ－４ 항체 또는 항-ｐｄ－１ 항체와 조합한 ｉｌ－２ｒ베타-선택적 효현제 - Google Patents

항-ｃｔｌａ－４ 항체 또는 항-ｐｄ－１ 항체와 조합한 ｉｌ－２ｒ베타-선택적 효현제 Download PDF

Info

Publication number
KR102410090B1
KR102410090B1 KR1020167023162A KR20167023162A KR102410090B1 KR 102410090 B1 KR102410090 B1 KR 102410090B1 KR 1020167023162 A KR1020167023162 A KR 1020167023162A KR 20167023162 A KR20167023162 A KR 20167023162A KR 102410090 B1 KR102410090 B1 KR 102410090B1
Authority
KR
South Korea
Prior art keywords
day
cancer
antibody
ctla
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167023162A
Other languages
English (en)
Korean (ko)
Other versions
KR20160122748A (ko
Inventor
무랄리 크리쉬나 아데팔리
데보라 에이치 차리치
세마 칸탁
스티븐 로버트 리
Original Assignee
넥타르 테라퓨틱스 (인디아) 프라이빗 리미티드
넥타르 테라퓨틱스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53055076&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102410090(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 넥타르 테라퓨틱스 (인디아) 프라이빗 리미티드, 넥타르 테라퓨틱스 filed Critical 넥타르 테라퓨틱스 (인디아) 프라이빗 리미티드
Publication of KR20160122748A publication Critical patent/KR20160122748A/ko
Application granted granted Critical
Publication of KR102410090B1 publication Critical patent/KR102410090B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
KR1020167023162A 2014-02-21 2015-02-20 항-ｃｔｌａ－４ 항체 또는 항-ｐｄ－１ 항체와 조합한 ｉｌ－２ｒ베타-선택적 효현제 Active KR102410090B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN499/DEL/2014 2014-02-21
IN499DE2014 2014-02-21
IN3087/DEL/2014 2014-10-29
IN3087DE2014 2014-10-29
PCT/IN2015/000099 WO2015125159A1 (en) 2014-02-21 2015-02-20 Il-2rbeta-selective agonists in combination with an anti-ctla-4 antibody or an an anti-pd-1 antibody

Publications (2)

Publication Number Publication Date
KR20160122748A KR20160122748A (ko) 2016-10-24
KR102410090B1 true KR102410090B1 (ko) 2022-06-16

Family

ID=53055076

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167023162A Active KR102410090B1 (ko) 2014-02-21 2015-02-20 항-ｃｔｌａ－４ 항체 또는 항-ｐｄ－１ 항체와 조합한 ｉｌ－２ｒ베타-선택적 효현제

Country Status (21)

Country Link
US (3) US10010587B2 (enExample)
EP (2) EP3834838A1 (enExample)
JP (3) JP6963385B2 (enExample)
KR (1) KR102410090B1 (enExample)
CN (1) CN106132438B (enExample)
AU (3) AU2015220408B2 (enExample)
CA (1) CA2937660A1 (enExample)
CY (1) CY1124226T1 (enExample)
DK (1) DK3134123T3 (enExample)
ES (1) ES2872848T3 (enExample)
HR (1) HRP20210377T1 (enExample)
HU (1) HUE053982T2 (enExample)
IL (1) IL247320B (enExample)
LT (1) LT3134123T (enExample)
MX (2) MX385194B (enExample)
PL (1) PL3134123T3 (enExample)
PT (1) PT3134123T (enExample)
RS (1) RS61661B1 (enExample)
SI (1) SI3134123T1 (enExample)
SM (1) SMT202100191T1 (enExample)
WO (1) WO2015125159A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088446A1 (en) 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
AU2014360318B2 (en) 2013-12-05 2019-10-31 Rfemb Holdings, Llc Cancer immunotherapy by radiofrequency electrical membrane breakdown (RF-EMB)
AU2014361473B2 (en) 2013-12-12 2019-09-26 Jiangsu Hengrui Medicine Co., Ltd. PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
CN106132438B (zh) * 2014-02-21 2020-03-03 尼克塔治疗印度私人有限公司 与抗CTLA-4抗体或抗PD-1抗体组合的IL-2Rβ选择性激动剂
EP3134102B1 (en) 2014-04-24 2019-07-03 The Board of Trustees of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
JP6723249B2 (ja) 2015-01-30 2020-07-15 アールエフイーエムビー ホールディングス リミテッド ライアビリティ カンパニー 軟部組織を切除するためのシステムおよび方法
AU2016293674B2 (en) 2015-07-16 2019-11-21 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
ES2968226T3 (es) 2015-10-02 2024-05-08 Univ Wuerzburg J Maximilians GDF-15 como marcador de diagnóstico para predecir la evolución clínica de un tratamiento con bloqueadores de puntos de control inmunitario
US12233104B2 (en) 2015-10-08 2025-02-25 Nektar Therapeutics Combination of an IL-2RBETA-selective agonist and a long-acting IL-15 agonist
CN108601789A (zh) 2015-11-20 2018-09-28 生华生物科技股份有限公司 用于治疗癌症的四环喹诺酮类似物组合疗法
CA3011460A1 (en) * 2016-01-15 2017-07-20 Rfemb Holdings, Llc Immunologic treatment of cancer
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
WO2017165778A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
US20200330557A1 (en) * 2016-08-19 2020-10-22 Brooklyn Immunotherapeutics Llc Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer
US20190275133A1 (en) * 2016-11-10 2019-09-12 Nektar Therapeutics Immunotherapeutic tumor treatment method
IL267929B2 (en) * 2017-01-10 2023-03-01 Nektar Therapeutics Multi-armed polymer conjugates of tlr agonistic compounds and related immunotherapeutic methods
US11318164B2 (en) 2017-03-01 2022-05-03 Nektar Therapeutics Immunotherapeutic treatment method using an interleukin-2 receptor beta-selective agonist in combination with adoptive cell transfer therapy
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
US12054553B2 (en) 2017-05-02 2024-08-06 Nektar Therapeutics Immunotherapeutic tumor treatment method
WO2018217058A1 (en) * 2017-05-25 2018-11-29 Institute For Basic Science Anti-human interleukin-2 antibodies and uses thereof
US11542312B2 (en) 2017-06-19 2023-01-03 Medicenna Therapeutics, Inc. IL-2 superagonists in combination with anti-PD-1 antibodies
CA3072320A1 (en) * 2017-08-17 2019-02-21 Nektar Therapeutics Immunotherapeutic tumor treatment method
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. Anti-cd137 molecules and use thereof
CN111315397A (zh) * 2017-11-06 2020-06-19 百时美施贵宝公司 治疗肿瘤的方法
EP3706770A4 (en) * 2017-11-07 2021-10-27 Nektar Therapeutics IMMUNOTHERAPEUTIC COMBINATION FOR THE TREATMENT OF CANCER
US20200317784A1 (en) * 2017-11-13 2020-10-08 Bioxcel Therapeutics, Inc. Methods and compositions for treating cancer by modifying multiple arms of the immune system
PH12020550661A1 (en) 2017-11-21 2021-04-19 Univ Leland Stanford Junior Partial agonists of interleukin-2
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
AU2019227294B2 (en) 2018-02-15 2023-06-15 Senhwa Biosciences, Inc. Quinolone analogs and their salts, compositions, and method for their use
BR112020018539A2 (pt) 2018-03-23 2020-12-29 Bristol-Myers Squibb Company Anticorpos contra mica e/ou micb e usos dos mesmos
MX2020009857A (es) * 2018-03-28 2021-01-08 Ascendis Pharma Oncology Div A/S Conjugados de interleucina-2 (il-2).
MX2020012252A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina 12 activables y metodos de uso de los mismos.
MX2020012251A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
WO2020095184A1 (en) 2018-11-05 2020-05-14 Pfizer Inc. Combinations for treating cancer
WO2020095183A1 (en) 2018-11-05 2020-05-14 Pfizer Inc. Combination for treating cancer
KR20210092769A (ko) 2018-11-16 2021-07-26 브리스톨-마이어스 스큅 컴퍼니 항-nkg2a 항체 및 그의 용도
KR20220023988A (ko) 2019-05-14 2022-03-03 웨어울프 세라퓨틱스, 인크. 분리 모이어티 및 이의 사용 방법
CA3155981A1 (en) 2019-11-14 2021-05-20 William Winston Activatable cytokine polypeptides and methods of use thereof
KR20220140514A (ko) 2020-01-10 2022-10-18 브라이트 피크 테라퓨틱스 아게 변형된 il-2 폴리펩타이드 및 그의 용도
MX2022008771A (es) 2020-01-14 2022-10-07 Synthekine Inc Metodos y composiciones de muteinas de il2 sesgadas.
KR20230015954A (ko) * 2020-05-26 2023-01-31 리제너론 파마슈티칼스 인코포레이티드 Pd-1 억제제의 투여에 의한 자궁경부암의 치료 방법
BR112022022826A2 (pt) 2020-06-03 2022-12-13 Ascendis Pharma Oncology Div A/S Sequências de il-2 e usos das mesmas
WO2022098954A1 (en) 2020-11-06 2022-05-12 Nektar Therapeutics Tlr agonist compounds and related cancer immunotherapy methods
CA3200687A1 (en) 2020-11-10 2022-05-19 Catalym Gmbh Anti-gdf15 antibody and a dosage regimen for the treatment of cancer
WO2022146947A1 (en) 2020-12-28 2022-07-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
CA3196999A1 (en) 2020-12-28 2022-07-07 Masano HUANG Methods of treating tumors
TW202304517A (zh) * 2021-03-29 2023-02-01 大陸商北京軒義醫藥科技有限公司 蛋白—大分子綴合物及其使用方法
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
TW202313679A (zh) * 2021-06-03 2023-04-01 美商欣爍克斯公司 包含il-2接合物及pd-1拮抗劑之頭頸癌組合療法
WO2023281483A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Modified tnf-antibodies and uses thereof
IL317319A (en) 2022-06-02 2025-01-01 Bristol Myers Squibb Co Antibody compounds and methods of using them
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121168A1 (en) * 2005-05-09 2006-11-16 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2012065086A1 (en) * 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6498165B1 (en) * 1999-06-30 2002-12-24 Merck & Co., Inc. Src kinase inhibitor compounds
SI1758610T1 (sl) * 2004-05-20 2012-11-30 Zymogenetics Inc Postopek za tretiranje raka z uporabo il in terapije z monoklonalnimi protitelesi
CA2611823C (en) 2005-06-16 2013-07-30 Nektar Therapeutics Al, Corporation Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
WO2012065079A1 (en) 2010-11-12 2012-05-18 Endocyte, Inc. Methods of treating cancer
MX360254B (es) * 2011-03-10 2018-10-26 Pfizer Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer.
CN106132438B (zh) * 2014-02-21 2020-03-03 尼克塔治疗印度私人有限公司 与抗CTLA-4抗体或抗PD-1抗体组合的IL-2Rβ选择性激动剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121168A1 (en) * 2005-05-09 2006-11-16 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2012065086A1 (en) * 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer

Also Published As

Publication number Publication date
AU2015220408A1 (en) 2016-08-11
US20200368321A1 (en) 2020-11-26
IL247320B (en) 2022-09-01
ES2872848T3 (es) 2021-11-02
MX2016010870A (es) 2016-10-26
US20180344810A1 (en) 2018-12-06
US20170128539A1 (en) 2017-05-11
JP2021073296A (ja) 2021-05-13
DK3134123T3 (da) 2021-04-06
MX385194B (es) 2025-03-14
CY1124226T1 (el) 2022-05-27
KR20160122748A (ko) 2016-10-24
US10010587B2 (en) 2018-07-03
IL247320A0 (en) 2016-09-29
CA2937660A1 (en) 2015-08-27
PL3134123T3 (pl) 2021-07-12
CN106132438A (zh) 2016-11-16
LT3134123T (lt) 2021-04-12
JP6963385B2 (ja) 2021-11-10
RS61661B1 (sr) 2021-04-29
EP3134123B1 (en) 2021-02-17
JP2017506264A (ja) 2017-03-02
CN106132438B (zh) 2020-03-03
WO2015125159A1 (en) 2015-08-27
AU2022203550A1 (en) 2022-06-16
AU2020213296A1 (en) 2020-08-27
EP3834838A1 (en) 2021-06-16
JP2019077723A (ja) 2019-05-23
HRP20210377T1 (hr) 2021-04-16
EP3134123A1 (en) 2017-03-01
SMT202100191T1 (it) 2021-05-07
PT3134123T (pt) 2021-03-22
US10786552B2 (en) 2020-09-29
HUE053982T2 (hu) 2021-08-30
SI3134123T1 (sl) 2021-08-31
MX2021009926A (es) 2021-09-21
AU2015220408B2 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
KR102410090B1 (ko) 항-ｃｔｌａ－４ 항체 또는 항-ｐｄ－１ 항체와 조합한 ｉｌ－２ｒ베타-선택적 효현제
KR20190105568A (ko) 종양의 면역 요법적 치료 방법
US20200317784A1 (en) Methods and compositions for treating cancer by modifying multiple arms of the immune system
WO2020176797A1 (en) Immunotherapeutic combination for treating cancer
JP7672342B2 (ja) 細胞免疫療法を増強するための方法
JP2021020921A (ja) 腫瘍微小環境に影響する抗癌剤と組み合わせたβ−グルカン
JP7611136B2 (ja) 別の薬理学的に活性な薬剤と組み合わせた長時間作用型インターロイキン－１５受容体作動薬
KR102861230B1 (ko) Il-2r베타-선택적 효현제 및 지속 작용성 il-15 효현제의 조합
KR20190051983A (ko) 암의 치료를 위한 abx196을 포함하는 조합물
HK40056474A (en) Il-2rbeta-selective agonists in combination with an anti-pd-1 antibody
RU2817047C2 (ru) Новый подход к лечению рака с применением иммуномодуляции

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160824

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200212

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210530

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220311

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220614

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220614

End annual number: 3

Start annual number: 1

PG1601 Publication of registration